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CLINICAL STUDY
Abstract 
Objective 
To look into the relation between parathyroid hormone and abnormal glucose homeostasis in 
chronic renal failure patients on regular hemodialysis.  
Methods 
41 subjects, with chronic renal failure, and on regular hemodialysis (28 male, 13 female; age 
range 19-64 years). Full history and clinical examination were taken for every patient. In 
addition, ten age and sex matched healthy persons were selected randomly as control group. 
Informed consent was obtained. All patients were investigated to determine serum creatinine, 
calcium, phosphorus, alkaline phosphatase, parathyroid hormone, fasting glucose, and 
fasting insulin. Homeostasis module assessment of insulin resistance was calculated as a 
measure of insulin resistance, Homeostasis module assessment of beta cell was calculated as a 
measure of pancreatic beta cell function. The uremic patients were classified into two groups: 
group A included 24 patients with plasma parathyroid hormone levels < 450 pg/ ml and 
group B included 17 patients with plasma parathyroid hormone level !450 pg/ml.  
Results 
There is a marked increase in fasting insulin level in all patients versus control associated 
with increased homeostasis module assessment of insulin resistance, an index for insulin 
resistance. Significant negative correlation is found between parathyroid hormone and fasting 
insulin and homeostasis module assessment of insulin resistance in uremic patients. Patients 
with severe hyperparathyroidism have relatively more impaired pancreatic beta cell function 
in comparison to those with mild hyperparathyroidism. The pulsed dose of intravenous 
 1-cholecalciferol is associated with low parathormone level and high serum calcium.  
Conclusion 
 Insulin resistance is a constant feature of chronic renal failure patients under hemodialysis 
therapy, while secondary hyperparathyroidism is linked negatively to beta cell function. 
Intermittent pulsed intravenous alphacalcidol is an effective method of lowering high serum 
parathyroid hormone and is associated with improvement of beta cell function without 
significant effect on insulin resistance.  
 
Key words: Secondary hyperparathyroidism, one alpha therapy, parathormone, insulin 
sensitivity, hemodialysis  
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Introduction 
 
hronic renal failure is a major health 
problem in Egypt, and the number of 
patients on regular hemodialysis is 
increasing nowadays. At the same time, its 
different lines of therapy (conservative, 
dialysis, and transplantation) open wide 
hopes for long term survival of uremic 
patients.  
Increased secretion of parathyroid hormone 
(PTH) is common in patients with chronic 
renal failure, and the excess blood levels of 
PTH could be deleterious to many organ 
systems 1.  A variety of symptoms and signs 
including encephalopathy, neuropathy, 
dialysis dementia, reduced left ventricular 
ejection fraction, impaired insulin secretion, 
glucose intolerance, hyperlipidaemia, soft 
tissue calcification, bone resorption, pruritis, 
immunological disturbances, and sexual 
dysfunction are encountered in patients 
with uremia2.  These manifestations 
contribute to the uremic syndrome and at 
least part of their pathogenesis has been 
attributed to PTH as a uremic toxin, and it is 
thought that such actions of PTH are 
mediated by an increase in intracellular 
calcium 2.     
Uremic patients are thought to be insulin 
resistant and about half of them were found 
to have impaired glucose tolerance 3. The 
insulin resistance is a characteristic feature 
of uremic patients; a problem that could be 
partially ameliorated both by hemodialysis 
and by the chronic ambulatory peritoneal 
dialysis 4,5. 
Some evidences suggest a role for PTH in 
the pathogenesis of deranged beta cell 
function of uremia. Early studies reported 
that PTH has a role in the problem of insulin 
resistance 6. Subsequent investigations using 
clamp techniques demonstrated that the 
development of glucose intolerance in 
uremic dogs could be prevented by 
parathyroidectomy 7.  Administration of 
PTH to rats with normal renal function 
increased the resting cytosolic calcium, 
decreased the ATP content and impaired 
insulin release through ATP-dependent K-
channels8. Pancreatic islets are apparently a 
PTH target; PTH stimulates cAMP 
production and possibly also protein kinase 
C in a calcium-dependent fashion 9. Also, it 
was suggested that uremic patients with 
elevated serum PTH were found to be 
severely insulin resistant and 
hyperinsulinemic and intravenous vitamin 
D treatment led to a significant reduction of 
serum PTH levels and to complete 
normalization of insulin sensitivity in 
hemodialysis patients 10.  
However, the exact effect of hyper- 
parathyroidism on different parameters of 
glucose homeostasis, and the effect of 
lowering serum PTH by one alpha 
hydroxycholecalciferol therapy still need 
further evaluation. It is theoretically possible 
that the deficiency of 1,25 (OH)2D3 
commonly encountered in patients with 
CRF plays a role in the impaired insulin 
secretion encountered in these patients11.   
The aim of the study is to look into the 
relation between serum PTH and 
parameters of glucose homeostasis and to 
analyze the effect of lowering PTH on these 
parameters.  
 
Materials and Methods 
 
The present study was conducted on forty 
one subjects suffering from chronic renal 
failure due to different intrinsic renal causes 
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who were on regular hemodialysis sessions. 
Their ages range from 19 to 64 years. They 
were 28 Males and 13 females. They were 
selected randomly from inpatient and 
outpatient clinics  of Internal Medicine 
Department of Mansoura University 
Hospital  Cairo Egypt.         
Full history was taken for every subject 
including name, age, sex, duration of 
dialysis therapy, cause of the original 
kidney disease, dry weight, number of 
sessions per week, duration of session, type 
of the dialyzer used, associated 
complications during the sessions, 
associated medical disorders (IHD, 
hypertension, DM), and medications 
received. Cases with diabetes mellitus, cases 
with impaired glucose tolerance, and cases 
taking any medications that affect 
carbohydrate metabolism were excluded. 
In addition, 10 healthy volunteers age and 
sex matched selected randomly as a 
reference (control) group. Informed consents 
were obtained from all subjects (patients 
and control) in the study. All persons of the 
study were subjected to full laboratory 
investigation to determine serum creatinine, 
calcium, phosphorus, alkaline phosphatase, 
PTH, blood hemoglobin, fasting glucose, 
and fasting insulin. HOMA-IR was 
calculated as a measurement of insulin 
resistance, also HOMA-B was calculated as 
a measurement of pancreatic beta cell 
function. 
The patients were classified into two groups 
according to plasma PTH level. Group A; 
included patients with plasma PTH level 
less than 450 pg/ml. This group included 24 
patients 15 males and 9 females. Group B; 
included patients with plasma PTH level 
more than 450 pg/ml. This group included 
17 patients 13 males and 4 females. 
Ten patients from those of group B have 
been selected randomly to receive pulsed 
doses of one alpha-cholecalciferol in the 
form of 1 microgram I.V. thrice weekly at 
the end of the hemodialysis session for four 
consecutive months. After the termination 
of the pulsed dose of one alpha-
cholecalciferol, the patients were returned 
back to their oral dose of 1 D-cholecalciferol. 
Complete laboratory investigations were  
performed for all the patients and the 
control at the beginning of the study, and 
four months later after termination of the 
pulsed dose of 1 D-cholecalciferol for all 
patients who received the pulsed dosage of 
1 D-cholecalciferol. 
Insulin resistance was measured using 
HOMA-IR test, while, pancreatic beta cell 
function was measured using HOMA-B test 
which were measured according as 
follows12:  
HOMA-IR = (fasting insulin x fasting 
glucose in mmol/L) / 22.5 
HOMA-B = (20 x fasting insulin) / (fasting 
glucose in mmol/L – 3.5) 
Statistical analysis: The statistical analysis of 
the present work was done by IBM personal 
computer using EXCEL statistical program, 
accepted level of significance for Probability 
value is 0.05.  
Chi square (X2) test with Yates correction or 
fisher, S exact test tested difference in 
prevalence, where applicable. Student t-test 
or Mann-Whiteny test analyzed continuous 
variables expressed as mean and standard 
deviation, where applicable.   
 
Results 
 
The detail of the results recorded in this 
study is outlined in Tables 1-5. Further 
interpretation of the results and data 
comparison is mentioned in the discussion. 
 
Discussion 
 
Abnormal glucose homeostasis has been a 
well known feature of uremic patients for 
many years. Several studies demonstrated 
the presence of insulin resistance and 
impaired glucose tolerance in uremic 
patients 13, 14. Others demonstrated 
pancreatic beta cell dysfunction in uremia 14, 
15. The problem of abnormal glucose 
homeostasis may be responsible for the 
increased incidence of atherosclerosis and 
cardiovascular morbidity in uremic patients 
16, which can account for high mortality 
rates in these patients. 
Patients with chronic renal failure (CRF) in 
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Table 1: Clinical data and anthropometric measurements for the patients versus controls and 
group A (PTH level < 450 pg/ml) versus group B (PTH level ! 450 pg/ml) 
 
GROUPS 
Sex Age (years) 
HD (ys) 
Duration BMI SBP DBP IHD HTN 
Count (%) Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD No No 
Control 
N = 10 
M: 7(70%) 
F: 3(30%) 36.9±5.8 --------- 23.7±3.1 126.4±10 73.5±8.2 -------- --------- 
All patients 
N= 41 
M: 28(68%) 
F: 13(32%) 51±10.5 5.2±3.7 25.6±4.6 127±23 76.5±13 
 
9 
 
 
13 
Statistical 
analysis 
Chi square = 
0.011 
p = 0.9 
P 
< 0.0001* ------- P = 0.04* P = 0.56 P = 0.48   
Group A 
N = 24 
M: 15(62%) 
F: 9(38%) 50.7±12.3 4.2±3.1 24.5±3.3 129.5±19 77.9±11.4 7 7 
Group B 
N= 17 
M: 13(76%) 
F: 4(23%) 51.2±8 6.5±4.2 27.2±5.7 124±27.4 74.7±15 2 6 
Statistical 
analysis 
*Chi square = 
0.89 
p = 0.34 
#P = 0.87 P = 0.07 P = 0.07 P = 0.48 P = 0.45 p = 0.41 p = 0.41 
 
*Chi square = 0.488.   #P value: Probability value 
 
Table 2: Laboratory data for the patients versus controls and group A (PTH level < 450 pg/ml) 
versus group B (PTH level ! 450 pg/ml) 
Features Creat. mg/dl 
0BCa 
mg/ dl 
P 
mg/dl 
AP 
KAu/d
l 
PTH 
Pg/ml 
Hb 
gm/dl 
FBG 
Mg/d
l 
FSI 
I.U/ml 
HOM
A 
-IR 
HOMA 
-B 
Control 
(n=10) 1.1±0.2 10.7±0.3 3±0.5 5.5±1.4 31±3.7 14±1.2 96±7 6.6±0.9 1.5±0.3 76.7±18.5 
Patients 
(n=41) 10.1±3.4 8.8±1.5 7±1.6 14±6.1 539±647 
10.4±0.
9 93±12 
10.5±6.
7 2.5±1.7 140.2±100 
P value 
P1 <0.001* <0.001* <0.001* 0.001* <0.001** 0.001* 0.46 <0.001* <0.001* 0.08 
Group A 
(n=24) 9.6±2.8 9.3±1.2 6.4±1.3 12.7±5 137±86 10.3±1 92±10 12±6.2 2.8±1.6 157±76.2 
Group B 
(n=17) 10.6±4 8±1.6 7.8±1.6 15.9±7 1107±672 
10.4±0.
9 95±14 8.6±7.2 2.1±1.8 116.2±125 
P value 
(P2) 
 
0.4 0.004* 0.004* 0.1 0.001** 0.9 0.4 0.12 0.08 0.01** 
 
* T- test                     ** Mann-Whiteny test.         P value: Probability value 
P1: comparison between patients versus control. P2: comparison between patients with PTH level above 
versus below 450 pg/ml.  
The mean levels of serum PTH, creatinine, phosphate, alkaline phosphatase, fasting insulin are higher in 
the uremic patients than control and low levels of hemoglobin & serum calcium in uremic patients. 
HOMA-IR is significantly higher in uremic patients than control.  
In comparing the fasting serum insulin, glucose, HOMA-IR, and HOMA-B in between patients with 
severely elevated (group B) and those with moderately elevated serum PTH (group A). there is no 
significant difference in fasting glucose, fasting insulin and HOMA-IR. While HOMA-B is significantly 
lower in severe HPT 
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Table 3: Comparison between patients with moderate anemia ((Hb<10.5 gm/dl) and patients 
with mild anemia (Hb>10.5 gm/dl) as regard insulin sensitivity for all patients  
HOMA-B HOMA-IR Fasting  glucosemg/dl 
Fasting Insulin
IU/ml Features 
156.2±96.6 2.5 ± 1.8 89 ± 11.8 11 ± 7 
Mildly anemic 
patients
N= 21 
123.3±103 2.4± 1.6 96 ± 10.6 10 ± 6.2 
Moderately 
anemic patients
N=20 
0.2 0.5 0.05 0.7 P value 
* T- test, ** Mann-Whiteny test. P value: Probability value 
  
Table 4: Correlation between laboratory indices glucose homeostasis and some laboratory data 
in hemodialysis patients (n = 41) 
Features  Calcium Phosphorus Alk. Phosphatase Creatinine Hemoglobin 
Fasting 
insulin 
r 
p 
0.5 
0.003 
-0.1 
0.5 
-.24 
0.12 
-.04 
0.8 
0.04 
0.8 
Fasting 
glucose 
r 
p 
0.03 
0.85 
-.02 
0.99 
0.004 
0.9 
-.15 
0.3 
0.3 
0.06 
HOMA-IR r p 
0.43 
0.006 
-.13 
0.4 
-0.2 
0.2 
-.06 
0.72 
0.08 
0.6 
HOMA-B** rs p 
0.41 
0.008 
-0.05 
0.5 
-0.24 
0.13 
0.03 
0.8 
02 
0.3 
There is no significant correlation between hemoglobin level and any of the parameters of glucose  
homeostasis. There is significant negative correlation between serum PTH and fasting insulin, HOMA-B 
(a marker of B cell function). this correlation does not reach the level of statistical significance (p = 0.07). 
but; there is a significant negative correlation between PTH and HOMA-IR index, a marker of insulin 
resistance. 
 
Table 5: Laboratory data of the studied patients (10 patients) before and after 4 months 
intravenous pulsed dose of one alpha cholecalciferol 
Features 
Creati
nine 
mg/dl 
Ca 
mg/dl 
P 
mg/dl 
AK 
KAU/dl 
PTH 
Pg/ml 
FBG 
mg/dl 
FSI 
IU/ml 
HOMA
-IR HOMA-B 
Before 
M±SD 
13.7±1
.6 
8.1±0.
5 8.3±1.7 15.6±6.4 1251±597 93±14 7.5±5.5 1.7±1.2 106±117 
After 
M±SD 
12.3±1
.3 
9.5±0.
6 7.2±1.1 13.2±2.6 827±202 88±7 12.6±4.7 2.8±1.2 181±48 
P value 0.041* 0.002* 0.3 0.24 0.09 0.49 0.18 0.18 0.02** 
* T- test                     ** Mann-Whiteny test.     P value: Probability value 
This table shows the effect of lowering serum PTH by intravenous pulsed alphacalcidol on glucose 
homeostasis data. There is significant increase in serum calcium and non-significant decrease in serum 
PTH and significant increase in beta cell function (measured by HOMA-B).    
 
 
the current work have significantly lower 
serum calcium, and significantly higher 
serum phosphorus than that of the control 
group. These changes reflect well-known 
problems in CRF that were previously 
reported 17. This denotes that although these 
patients were under hemodialysis therapy, 
they were far from being ideally controlled. 
The predialysis serum creatinine was 
greatly increased. 
The higher serum PTH in the uremic 
patients indicates the well known major 
Mohammed Abdulaziz et al 
49 
J T U Med Sc 2008; 3(1)
 
Figure 1: The relationship between 
parathyroid hormone and fasting insulin 
 
Figure 2: The relationship between 
parathyroid hormone versus homeostasis 
module assessment of insulin resistance 
and beta cell function 
 
 
problem affecting these patients which is a 
secondary hyperparathyroidism in CRF 
patients 18.  
Since the reduced PTH degradation and 
clearance affect mainly the inactive PTH 
fragments, it is unlikely to cause alternation 
in the intact PTH steady state concentration
19. Therefore, uremic hyperparathyroidism is 
mainly due to an increase in bioactive PTH 
synthesis and a release by the parathyroid 
gland. The stimulatory factors of 
parathyroid hormone synthesis and 
secretion include hypocalcaemia, 
hyperphosphatemia, and vitamin D3 
metabolic abnormalities 20. Thus, there are 
additional factors that may contribute to 
hyperparathyroidism in chronic renal 
failure as acidosis and uremic toxins 21. 
Increased fasting insulin in uremic patients 
can be attributed to decrease in the 
metabolic clearance of insulin 22.  Impaired 
degradation of insulin in non-renal tissues 
(liver and muscle) may also contribute to the 
prolonged half life of insulin in uremic 
patients 22. This increase in fasting insulin is 
not associated with any significant change 
in fasting blood glucose that may give an 
impression of resistance to the action of 
insulin. Moreover, the higher HOMA-IR 
value in CRF documents the presence of 
insulin resistance in CRF patients in the 
present work.  
These results are consistent with the study 
of Tuzeu et al 23, who demonstrated that 
mean insulin level is significantly elevated 
in uremic patients versus control group, and 
also, demonstrated insulin resistance in the 
uremic patients of the study using HOMA-
IR as a measurement of insulin resistance. 
Also, these results are in accord with those 
of Sechi et al 24 who reported that the 
problem of insulin resistance is found in 
uremic patients and even in early renal 
impairment; alternation of glucose 
metabolism became evident only when 
creatinine clearance was < 50ml/min. A 
multitude of many previous studies 
reported insulin resistance in uremic 
patients 6, 25, 26. 
Many factors contribute to the problem of 
insulin resistance in uremia.  Accumulation 
of some uremic toxin(s) may be responsible
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for decreased insulin sensitivity. When 
uremic serum was incubated with tissues 
from normal animals, glucose utilization 
and oxidative phosphorylation were 
inhibited 13. 
Mak  and his coworkers28 demonstrated 
that, glucose tolerance and insulin 
sensitivity were improved significantly after 
protein restriction, or dialysis, thus, insulin 
resistance in uremia can be improved by 
dialysis or a low-protein diet. This may 
suggest that, accumulation of dialyzable 
toxins from protein metabolism is 
responsible for impaired glucose tolerance 
and decreased insulin sensitivity in uremic 
patients. 
Anemia can be attributed to shortened 
erythrocyte survival, blood loss, and failure 
of the bone marrow to enhance red cell 
production to compensate their increased 
demand 28, 29. Several studies demonstrated 
that anemia is a major pathogenic factor 
behind insulin resistance in chronic renal 
failure 30. Spaia and his co-workers 30  
proved the beneficial effect of EPO 
treatment on insulin resistance in dialysis 
patients. Tuzeu and his co-workers 23 
demonstrated that correction of anemia 
using erythropoietin normalized insulin 
sensitivity in uremia. Furthermore, they 
demonstrated that improvement in insulin 
sensitivity is positively correlated with 
duration of EPO therapy. 
Plasma cell differentiation antigen 1 (PC-1) 
is an inhibitor of insulin receptor tyrosine 
kinase and it is thought to be one of the 
factors behind insulin resistance in uremia 
31. Stevanovic and his co-workers 32 found 
increased lymphocyte PC-1 activity in 
uremic patients over the control, and two 
months after EPO therapy, lymphocyte PC-1 
activity decreased significantly, suggesting 
that an effect of PC-1 expression could be 
implicated in the amelioration of insulin 
resistance in uremic patients. 
The uremic patients have more insulin 
resistance in moderate anemia than mild 
anemia. This may be due to the fact that 
some of them have been under EPO therapy 
while others received frequent blood 
transfusion. Moreover, in contrast to the 
previous study of Mak 28 . There is no 
significant correlation between hemoglobin 
level and any of the parameters of glucose 
homeostasis in the present work. This may 
be attributed to the observation that many 
patients were already receiving EPO 
therapy and that the degree of anemia is 
much less than that reported in the previous 
studies before correction. 
Lindall and his co-workers 7  reported that 
uremic patients on hemodialysis with 
normal PTH levels had a normal insulin 
response to I.V glucose, while those with 
hyperparathyroidism showed disturbed 
insulin responses which was normalized 
after parathyroidectomy. 
The negative correlation between serum 
PTH and fasting insulin and HOMA-B (an 
indicator of beta cell function) and HOMA-
IR index (a marker of insulin resistance), 
denote that PTH has an ameliorating effect 
on insulin resistance or, in other words, it is 
at least not linked to the worsening of 
insulin resistance. This is in obvious contrast 
with previously cited researches 7, 33 
demonstrating the role of PTH in the 
problem of insulin resistance. 
The patients with severe hyper- 
parathyroidism (HPT) have significantly 
low HOMA-B than those patients with 
moderate HPT. This may denote that the 
higher PTH level may have a deleterious 
effect on beta cell function. 
In our study, the intravenous pulsed 
alphacalcidol thrice weekly resulted in 
significant increase in serum calcium and 
improve the beta cell function (measured by 
HOMA-B). Whether these changes were due 
to lowering the PTH or an intrinsic effect of 
alphacalcidol or increased serum calcium 
level is open to speculations.    
Lindall 7 ,  Prager 33 , Amend 34,  and their co-
workers studied insulin resistance using 
insulin tolerance tests in six stable uremic 
patients with secondary hyper- 
parathyroidism prior to and after subtotal 
parathyroidectomy, the authors found that 
parathyroidectomy per se had no significant 
effect upon glucose utilization, or the 
resistance of the peripheral tissues to the 
action of exogenous insulin. This agrees 
with the finding of the present work of 
absence of significant improvement of
Mohammed Abdulaziz et al 
 
51 
J T U Med Sc 2008; 3(1) 
 
insulin resistance after lowering PTH with 
I.V. alphacalcidol. 
Mak 35 ,  Akmal 8 , and their co-workers 
studied the effect of PTH on glucose 
homeostasis using the hyperglycemic clamp 
technique in eight uremic children, and they 
found that lowering of PTH using high-dose 
phosphate binders and dietary restriction of 
phosphate led to improvement in pancreatic 
beta cell function and was not associated 
with any improvement in insulin resistance 
of the uremic children. 
Also, Mak and his co-workers 28 , used the 
hyperglycemic clamp studies to study 
insulin sensitivity in eight uremic patients. 
They demonstrated a negative correlation 
between glucose metabolic rate (a measure 
of insulin sensitivity) and PTH level, but this 
was possibly ascribed to the effect of 
changing the GFR with serum PTH level. 
The authors also, demonstrated that 
correction of hyperparathyroidism by 
subtotal parathyroidectomy did not 
improve the problem of insulin resistance in 
the parathyroidectomized uremic patients. 
Moreover, lowering of PTH by subtotal 
parathyroidectomy was associated with 
increased insulin secretion from pancreatic 
beta cells with amelioration of glucose 
tolerance 27 , which is consistent with the 
results of the present study. Furthermore, 
the observation of negative relation between 
PTH and beta cell function is consistent with 
the study of Fadda and his co-workers 37 
demonstrated that, excess PTH is 
responsible for the decreased insulin 
secretion by pancreatic beta cells. They 
found that, insulin secretion in 
parathyroidectomized uremic rats was 
better than the control uremic rats. They also 
demonstrated that PTH administration to 
non uremic normal rats decreased insulin 
release by the islets. 
published data indicate that excess PTH in 
uremia is associated with increased basal 
levels of calcium in many cells including 
pancreas 15, 37. Elevated basal level of 
calcium of pancreatic beta cells appears to 
be responsible for decreased insulin 
secretion in secondary hyperparathyroidism 
in CRF through reducing intracellular ATP 
content of the cells which is important in the 
process of insulin secretion. This is because 
ATP facilitates the closure of the ATP-
dependent potassium channels, which is 
followed by cell depolarization and 
subsequent activation of voltage-sensitive 
calcium channels  38. This was supported by 
Missry13 who demonstrated that the 
glucose-induced calcium signals from CRF 
rats was significantly smaller than that 
observed in islets from normal rats. 
The present results suggest that one alpha 
calcidol increased fasting insulin, and 
improved pancreatic beta cell functions. 
This is in harmony with previous studies 39, 
40 which showed the effect of one alpha 
cholecalciferol on glucose homeostasis using 
the hyperglycemic clamp techniques in 
eleven uremic patients.  That study reported 
that acute intravenous 1-alpha 
cholecalciferol increased insulin secretion 
and corrected glucose intolerance in uremic 
patients. But in contrast to our results, this 
increase in insulin secretion was not 
associated with any significant changes in 
PTH level or, ionized or total calcium. This 
demonstrates that one alpha cholecalciferol, 
appears to be a direct modulator of insulin 
release from the pancreatic beta cell in 
uremia independent of PTH and serum 
electrolyte concentrations. 
Available data indicate that pancreatic beta 
cells have a specific receptor protein for 1, 
25(OH)2D3 41. They found, in the chick, that 
the pancreatic islets possess receptor 
proteins for 1, 25(OH)2D3 through which it 
interacts with the pancreatic islets and 
modulates their insulin secretion. Likewise, 
it is still premature to confirm whether PTH 
modulation and vitamin D3 has a role in 
insulin resistance or insulin secretion and 
whether it acts through lowering PTH or 
through another different mechanism 
inherent to this molecule 42,43. 
In conclusion, hyperparathyroidism, insulin 
resistance, and beta cell dysfunction are 
common problems in CRF patients on 
hemodialysis. The excess PTH is 
significantly associated with beta cell 
dysfunction. Effective lowering of serum 
PTH by intravenous pulsed one alpha 
cholecalciferol or subtotal para- 
thyroidectomy can achieve better beta cell
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function but may not help the problem of 
insulin resistance. It is recommended that all 
CRF patients are investigated regarding 
glucose intolerance, insulin resistance, and 
beta cell function. Any drugs or chemicals 
that may deteriorate glucose tolerance 
should be avoided if possible. Using drugs 
that may improve insulin resistance and 
beta cell function can be beneficial to some 
cases; but this awaits further longitudinal 
studies. 
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